U.S. Judge Denies Class Certification for Wholesalers in EpiPen Pricing Lawsuit Against Mylan

In a significant development for litigation around the EpiPen pricing controversy, U.S. District Judge Eric C. Tostrud for the District of Minnesota denied class certification to a group of pharmaceutical wholesalers in a case against Mylan, the manufacturer of the EpiPen. Judge Tostrud concluded that the plaintiffs did not sufficiently demonstrate that the class was so numerous that joining all members would be impracticable under Rule 23(a)(1) of the Federal Rules of Civil Procedure. Furthermore, the plaintiffs failed to show that the representative parties would adequately protect the interests of the class as required by Rule 23(a)(4) or that questions of law or fact common to class members would predominate over questions affecting only individual members under Rule 23(b)(3). For more detailed information, you can access the original summary by following this link.